Bispecific antigen binding molecules targeting OX40 and FAP

US11780919B2 · kind B2 · utility

Assignee

• Hoffmann-La Roche Inc. · US

Inventors

• Maria Amann · Stintenberger Straße, CH
• Juergen Peter BACHL · Basel, CH
• Alexander BUJOTZEK · Penzberg, DE
• Carina CANTRILL · Basel, CH
• Harald Duerr · Starnberg, DE
• Janine FAIGLE · Penzberg, DE
• Sabine Imhof-Jung · Planegg, DE
• Christian Klein · Iffeldorf, DE
• Thomas Kraft · Penzberg, DE
• Estelle Marrer-Berger · Basel, CH
• Ekkehard Moessner · Kreuzlingen, CH
• Laurene POUSSE · Schlieren, CH
• Petra Rueger · Penzberg, DE
• Johannes SAM · Schlieren, CH
• Roland Staack · Penzberg, DE
• Dietrich Tuerck · Ulm, DE
• Pablo Umana · Wollerau, CH
• Joerg ZIELONKA · Schlieren, CH

Key dates

• Filing date: Mar 31, 2021
• Grant date: Oct 10, 2023
• Expiry date: Jun 19, 2041

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/94
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to novel bispecific antigen binding molecules, comprising at least two antigen binding domains capable of specific binding to OX40 and a particular antigen binding domain capable of specific binding to Fibroblast Activation Protein (FAP), and to methods of producing these molecules and to methods of using the same.